Genpact and STADA Renew Multi-Year Partnership to Enhance Finance Operations
Genpact (NYSE: G) and STADA (SAZ.DE) have renewed their multi-year partnership to enhance STADA's finance operations. The collaboration aims to derisk, scale, and simplify STADA's financial processes, driving competitive advantages. Since 2019, Genpact has leveraged automation and process-harmonization to improve STADA's critical operations, implementing technologies like Genpact's Cora APFlow.
The partnership has enhanced accuracy in accounts payable and receivable, improved data transparency, and allowed STADA's teams to focus on strategic initiatives. Genpact's expertise has been important in optimizing STADA's finance and procurement processes, from supplier invoicing to financial reporting. The companies are also collaborating on implementing advanced tools like S4HANA and generative AI.
Genpact (NYSE: G) e STADA (SAZ.DE) hanno rinnovato la loro partnership pluriennale per migliorare le operazioni finanziarie di STADA. La collaborazione mira a ridurre i rischi, scalare e semplificare i processi finanziari di STADA, offrendo vantaggi competitivi. Dal 2019, Genpact ha sfruttato l'automazione e l'armonizzazione dei processi per ottimizzare le funzioni critiche di STADA, implementando tecnologie come Cora APFlow di Genpact.
La partnership ha incrementato la precisione nelle contabilità fornitori e clienti, migliorato la trasparenza dei dati e permesso ai team di STADA di concentrarsi su iniziative strategiche. L'esperienza di Genpact è stata fondamentale per ottimizzare i processi finanziari e di approvvigionamento di STADA, dalla fatturazione dei fornitori alla reportistica finanziaria. Le aziende stanno inoltre collaborando all'implementazione di strumenti avanzati come S4HANA e intelligenza artificiale generativa.
Genpact (NYSE: G) y STADA (SAZ.DE) han renovado su asociación a largo plazo para mejorar las operaciones financieras de STADA. La colaboración tiene como objetivo reducir riesgos, escalar y simplificar los procesos financieros de STADA, generando ventajas competitivas. Desde 2019, Genpact ha aprovechado la automatización y la armonización de procesos para optimizar las operaciones críticas de STADA, implementando tecnologías como Cora APFlow de Genpact.
La asociación ha mejorado la precisión en cuentas por pagar y cobrar, aumentado la transparencia de datos y permitido que los equipos de STADA se concentren en iniciativas estratégicas. La experiencia de Genpact ha sido fundamental para optimizar los procesos financieros y de adquisición de STADA, desde la facturación de proveedores hasta la elaboración de informes financieros. Las empresas también están colaborando en la implementación de herramientas avanzadas como S4HANA y IA generativa.
Genpact (NYSE: G)와 STADA (SAZ.DE)는 다년간의 파트너십을 갱신하였습니다하여 STADA의 재무 운영을 개선합니다. 이 협력은 STADA의 재무 프로세스를 위험 최소화, 확대 및 간소화하는 것을 목표로 하여 경쟁 우위를 제공합니다. 2019년부터 Genpact는 자동화 및 프로세스 조화를 활용하여 STADA의 중요한 운영을 개선하였으며, Genpact의 Cora APFlow와 같은 기술을 구현해왔습니다.
이 파트너십은 계좌의 지급 및 수취 정확도를 개선하고 데이터 투명성을 높이며 STADA 팀이 전략적 이니셔티브에 집중할 수 있도록 했습니다. Genpact의 전문성은 STADA의 재무 및 조달 프로세스, 공급업체 청구에서 재무 보고서 작성까지 최적화하는 데 중요한 역할을 했습니다. 두 회사는 또한 S4HANA 및 생성적 AI와 같은 고급 도구의 구현에 대해 협력하고 있습니다.
Genpact (NYSE: G) et STADA (SAZ.DE) ont renouvelé leur partenariat pluriannuel afin d'améliorer les opérations financières de STADA. Cette collaboration vise à réduire les risques, étendre et simplifier les processus financiers de STADA, entraînant des avantages concurrentiels. Depuis 2019, Genpact a tiré parti de l'automatisation et de l'harmonisation des processus pour améliorer les opérations critiques de STADA, en mettant en œuvre des technologies telles que Cora APFlow de Genpact.
Le partenariat a amélioré la précision des comptes fournisseur et client, a renforcé la transparence des données et a permis aux équipes de STADA de se concentrer sur des initiatives stratégiques. L'expertise de Genpact a été essentielle pour optimiser les processus financiers et d'approvisionnement de STADA, de la facturation des fournisseurs à la reporting financier. Les entreprises collaborent également pour mettre en œuvre des outils avancés tels que S4HANA et l'IA générative.
Genpact (NYSE: G) und STADA (SAZ.DE) haben ihre mehrjährige Partnerschaft erneuert, um die Finanzoperationen von STADA zu verbessern. Die Zusammenarbeit zielt darauf ab, STADAs finanzielle Prozesse zu risikomindern, zu skalieren und zu vereinfachen, um wettbewerbliche Vorteile zu schaffen. Seit 2019 hat Genpact Automatisierung und Prozessharmonisierung genutzt, um die kritischen Operationen von STADA zu verbessern, einschließlich der Implementierung von Technologien wie Genpacts Cora APFlow.
Die Partnerschaft hat die Genauigkeit in der Debitoren- und Kreditorenbuchhaltung verbessert, die Daten-Transparenz erhöht und es den STADA-Teams ermöglicht, sich auf strategische Initiativen zu konzentrieren. Die Expertise von Genpact war entscheidend für die Optimierung von STADAs Finanz- und Beschaffungsprozessen, von der Rechnungsstellung der Lieferanten bis zur finanziellen Berichterstattung. Die Unternehmen arbeiten ebenfalls an der Implementierung fortschrittlicher Werkzeuge wie S4HANA und generative KI.
- Renewal of multi-year partnership between Genpact and STADA
- Implementation of automation and process-harmonization technologies
- Improved accuracy in critical processes like accounts payable and receivable
- Enhanced data transparency and streamlined operations
- Collaboration on implementing advanced tools like S4HANA and generative AI
- None.
Insights
The renewal of Genpact and STADA's multi-year partnership is a positive development for both companies. For Genpact, it solidifies their position in the life sciences and healthcare sector, potentially leading to stable revenue streams. The partnership's focus on leveraging data, technology and AI aligns with industry trends, positioning Genpact as an innovative leader in finance and accounting services.
For STADA, the partnership promises enhanced operational efficiency and cost reduction, important for maintaining competitiveness in the pharmaceutical industry. The implementation of advanced technologies like S4HANA and generative AI could lead to significant improvements in decision-making processes and regulatory compliance, potentially boosting STADA's market position.
However, investors should monitor the execution risks associated with implementing new technologies and the potential impact on short-term financials due to investment costs.
The partnership's focus on cutting-edge technologies is noteworthy. Genpact's Cora APFlow has already demonstrated its value in enhancing critical processes like accounts payable and receivable. The planned implementation of S4HANA, SAP's next-generation ERP system, could bring substantial improvements in real-time data processing and analytics capabilities.
The mention of generative AI is particularly intriguing. While its specific applications aren't detailed, it could potentially revolutionize areas like financial forecasting, risk assessment and automated reporting. However, integrating these advanced technologies requires careful change management and robust cybersecurity measures to mitigate potential risks.
Overall, this tech-forward approach positions both companies at the forefront of digital transformation in finance operations, potentially creating significant competitive advantages.
This partnership renewal reflects a broader trend in the pharmaceutical industry towards digital transformation and operational efficiency. As the sector faces increasing cost pressures and regulatory scrutiny, companies are turning to advanced technologies to streamline operations and improve decision-making.
STADA's focus on automating end-to-end processes like procure-to-pay and order-to-cash is particularly relevant, as these areas often represent significant cost centers for pharmaceutical companies. By freeing up internal teams to focus on high-value activities, STADA could potentially accelerate its growth and improve its competitive position.
For Genpact, this partnership strengthens its foothold in the lucrative life sciences and healthcare market. The company's ability to deliver tangible benefits to STADA could attract similar partnerships with other pharmaceutical firms, potentially driving future growth for Genpact in this sector.
Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages
"This renewal exemplifies our leadership in finance and accounting services," said Sanjiv Tandon, Global Business Unit Leader, Life Sciences and Healthcare, Genpact. "By combining this expertise with our digital leadership and industry knowledge, we will enhance STADA's decision-making with actionable finance data, automate key F&A processes, and support regulatory compliance – ultimately enabling the company to continuously scale and excel in its industry."
Since 2019, Genpact's partnership with STADA has centered on leveraging automation and process-harmonization to enhance critical operations. Implementing technologies such as Genpact's Cora APFlow has improved the accuracy of critical processes such as accounts payable and receivable, streamlined data transparency, and empowered STADA's teams to focus on strategic initiatives that drive business outcomes.
"STADA's rapid growth and complex operations require a scalable and efficient platform. Our partnership with Genpact has enabled us to create automated processes that handle end-to-end tasks like procure-to-pay and order-to-cash efficiently and cost-effectively," said Boris Döbler, Group Chief Financial Officer, STADA. "This allows our internal teams to focus on high-value activities. By leveraging data, analytics, and process automation, we're not only reducing costs but also improving accuracy, quality, and customer satisfaction."
Genpact has been instrumental in optimizing STADA's finance and procurement processes, from supplier invoicing to financial reporting, leveraging advanced technology and deep finance and accounting expertise. Based on this strong foundation, the companies also are partnering to implement and leverage tools and technologies like S4HANA and generative AI.
For more information on Genpact's capabilities and services for the life sciences and healthcare industries, visit here.
About Genpact
Genpact (NYSE: G) is a global professional services and solutions firm delivering outcomes that shape the future. Our 125,000+ people across 30+ countries are driven by our innate curiosity, entrepreneurial agility, and desire to create lasting value for clients. Powered by our purpose – the relentless pursuit of a world that works better for people – we serve and transform leading enterprises, including the Fortune Global 500, with our deep business and industry knowledge, digital operations services, and expertise in data, technology, and AI.
Get to know us at genpact.com and on LinkedIn, X, YouTube, and Facebook.
MEDIA CONTACT:
Sue Martenson
Genpact Media Relations
+1 978-905-9582
susan.martenson@genpact.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genpact-and-stada-renew-multi-year-partnership-to-enhance-finance-operations-302245419.html
SOURCE Genpact Ltd.
FAQ
What is the purpose of Genpact and STADA's renewed partnership?
How has Genpact (NYSE: G) improved STADA's financial operations since 2019?
What specific technologies are Genpact and STADA implementing in their partnership?
How does the partnership between Genpact (NYSE: G) and STADA benefit STADA's internal teams?
